B.Riley FBR Keeps Their Buy Rating on Intricon Corp

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Intricon Corp (NASDAQ: IIN), with a price target of $32. The company’s shares opened today at $29.90, equals to its 52-week high of $29.90.

According to TipRanks.com, D’silva is a 4-star analyst with an average return of 19.6% and a 56.1% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Kindred Biosciences, and Cytosorbents Corp.

Intricon Corp has an analyst consensus of Moderate Buy, with a price target consensus of $32.

See today’s analyst top recommended stocks >>

Intricon Corp’s market cap is currently $200.8M and has a P/E ratio of 109.36. The company has a Price to Book ratio of 9.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets.